Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B, Multi-Center, Open-Label, Single Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placental-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis.Sarcoidosis

Next Previous
Search
Trial Profile

A Phase 1B, Multi-Center, Open-Label, Single Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placental-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis.Sarcoidosis

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenplacel L (Primary)
  • Indications Pulmonary sarcoidosis
  • Focus Adverse reactions
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 06 Jan 2023 Results from the re-analysis of long term follow-up data from three legacy Phase 1, Phase 1b/2a and Phase 1b studies of Cenplacel-L presented in a Celularity Media Release.
    • 10 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 25 Jun 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top